CELGENE CORPORATION (NASDAQ:CELG) Files An 8-K Results of Operations and Financial ConditionITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On April 27, 2017, Celgene Corporation issued a press release announcing its financial results for its fiscal quarter ended March 31, 2017. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, that is furnished to this Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibit 99.1 Press Release dated April 27, 2017 announcing results for the quarter ended March 31, 2017.
This exhibit is furnished to Item 2.02 and shall not be deemed to be “filed.”
About CELGENE CORPORATION (NASDAQ:CELG)
Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company’s clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology. CELGENE CORPORATION (NASDAQ:CELG) Recent Trading Information
CELGENE CORPORATION (NASDAQ:CELG) closed its last trading session down -0.32 at 125.20 with 3,625,449 shares trading hands.
